NasdaqCM - Nasdaq Real Time Price USD

Cellectar Biosciences, Inc. (CLRB)

3.2004 -0.0996 (-3.01%)
As of 12:33 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
42,256.8280
38,960.6430
28,813.7730
24,131.2800
15,290.3490
Operating Income
-42,256.8280
-38,960.6430
-28,813.7730
-24,131.2800
-15,290.3490
Net Non Operating Interest Income Expense
582.9620
387.1470
152.5190
2.2840
10.8970
Other Income Expense
--
530.0000
--
6.6340
185.2800
Pretax Income
-51,043.8660
-38,043.4960
-28,661.2540
-24,122.3620
-15,094.1720
Tax Provision
--
-60.0000
-60.0000
--
--
Net Income Common Stockholders
-50,983.8660
-37,983.4960
-28,601.2540
-24,122.3620
-15,094.1720
Diluted NI Available to Com Stockholders
-50,983.8660
-37,983.4960
-28,601.2540
-24,122.3620
-15,094.1720
Basic EPS
-3.09
-3.11
-4.05
-4.35
-7.60
Diluted EPS
-3.09
-3.11
-4.05
-4.35
-7.60
Basic Average Shares
16,742.9360
12,221.5710
7,055.6650
5,551.5720
1,981.2650
Diluted Average Shares
16,742.9360
12,221.5710
7,055.6650
5,551.5720
1,981.2650
Total Operating Income as Reported
-42,256.8280
-38,960.6430
-28,813.7730
-24,131.2800
-15,290.3490
Total Expenses
42,256.8280
38,960.6430
28,813.7730
24,131.2800
15,290.3490
Net Income from Continuing & Discontinued Operation
-50,983.8660
-37,983.4960
-28,601.2540
-24,122.3620
-15,094.1720
Normalized Income
-42,083.8660
-38,981.6960
-28,601.2540
-24,122.3620
-15,279.4520
Interest Income
582.9620
387.1470
152.5190
2.2840
10.8970
Net Interest Income
582.9620
387.1470
152.5190
2.2840
10.8970
EBIT
-42,256.8280
-38,960.6430
-28,813.7730
-24,131.2800
-15,290.3490
EBITDA
-42,018.5200
-38,768.2680
-28,665.3380
-23,981.3650
-15,148.8960
Reconciled Depreciation
238.3080
192.3750
148.4350
149.9150
141.4530
Net Income from Continuing Operation Net Minority Interest
-50,983.8660
-37,983.4960
-28,601.2540
-24,122.3620
-15,094.1720
Total Unusual Items Excluding Goodwill
-8,900.0000
1,000.0000
--
--
185.2800
Total Unusual Items
-8,900.0000
1,000.0000
--
--
185.2800
Normalized EBITDA
-33,118.5200
-39,768.2680
-28,665.3380
-23,981.3650
-15,334.1760
Tax Rate for Calcs
--
0.0000
0.0000
--
--
Tax Effect of Unusual Items
--
1.8000
--
--
--
12/31/2020 - 11/10/2005

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ASMB Assembly Biosciences, Inc.
14.99
+3.17%
 
SPRO Spero Therapeutics, Inc.
1.5600
-1.89%
 
CYTK Cytokinetics, Incorporated
60.55
+1.71%
 
CTMX CytomX Therapeutics, Inc.
1.8600
-1.59%
 
ALGS Aligos Therapeutics, Inc.
0.6750
-1.96%
 
MDNAF Medicenna Therapeutics Corp.
1.6900
+0.90%
 
GLPG.AS Galapagos NV
26.98
-1.89%
 
RPHM Reneo Pharmaceuticals, Inc.
1.7600
+0.57%
 
TIL Instil Bio, Inc.
11.44
-0.52%
 
PDSB PDS Biotechnology Corporation
3.3050
-5.30%